IRIS
PATRIGNANI, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.741
EU - Europa 9.935
AS - Asia 9.570
SA - Sud America 1.164
AF - Africa 148
Continente sconosciuto - Info sul continente non disponibili 25
OC - Oceania 15
Totale 34.598
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.513
SG - Singapore 3.563
CN - Cina 2.990
UA - Ucraina 1.826
IE - Irlanda 1.433
GB - Regno Unito 1.314
TR - Turchia 1.253
RU - Federazione Russa 1.229
IT - Italia 985
BR - Brasile 965
SE - Svezia 906
VN - Vietnam 826
FR - Francia 824
DE - Germania 633
FI - Finlandia 378
IN - India 315
PL - Polonia 153
HK - Hong Kong 121
CA - Canada 111
AR - Argentina 86
MX - Messico 81
BD - Bangladesh 76
ZA - Sudafrica 59
KR - Corea 56
JP - Giappone 54
IQ - Iraq 53
CZ - Repubblica Ceca 47
BE - Belgio 45
ES - Italia 43
SA - Arabia Saudita 41
NL - Olanda 34
ID - Indonesia 29
EC - Ecuador 27
PK - Pakistan 25
CO - Colombia 24
UZ - Uzbekistan 22
AT - Austria 21
EU - Europa 21
IL - Israele 19
MA - Marocco 19
LT - Lituania 18
IR - Iran 16
AE - Emirati Arabi Uniti 15
PH - Filippine 15
VE - Venezuela 15
DZ - Algeria 14
PY - Paraguay 14
EG - Egitto 13
AU - Australia 12
CL - Cile 12
KE - Kenya 12
JO - Giordania 10
PE - Perù 10
TN - Tunisia 10
MY - Malesia 9
OM - Oman 9
AZ - Azerbaigian 8
JM - Giamaica 8
RO - Romania 7
BY - Bielorussia 6
GR - Grecia 6
HN - Honduras 6
KZ - Kazakistan 6
PS - Palestinian Territory 6
UY - Uruguay 6
LY - Libia 5
NP - Nepal 5
AL - Albania 4
AM - Armenia 4
BB - Barbados 4
BO - Bolivia 4
ET - Etiopia 4
LB - Libano 4
SN - Senegal 4
TH - Thailandia 4
BA - Bosnia-Erzegovina 3
CG - Congo 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
KW - Kuwait 3
PA - Panama 3
PT - Portogallo 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
BG - Bulgaria 2
BH - Bahrain 2
BN - Brunei Darussalam 2
CH - Svizzera 2
GA - Gabon 2
GT - Guatemala 2
HR - Croazia 2
HU - Ungheria 2
LK - Sri Lanka 2
MN - Mongolia 2
NG - Nigeria 2
NI - Nicaragua 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
RS - Serbia 2
TW - Taiwan 2
Totale 34.584
Salva come PNG Salva come JPEG
Città #
Singapore 2.450
Jacksonville 1.967
Chandler 1.728
San Jose 1.629
Dublin 1.423
Southend 1.002
Ashburn 762
Princeton 705
Dallas 698
Izmir 638
Beijing 606
Dearborn 568
Nanjing 494
Cambridge 324
Los Angeles 322
Wilmington 311
Ho Chi Minh City 281
Tongling 270
Hanoi 200
Nanchang 200
Santa Clara 193
The Dalles 186
Altamura 171
Buffalo 163
Boardman 157
Moscow 139
Chieti 138
Shenyang 132
New York 128
Woodbridge 120
Council Bluffs 117
Ann Arbor 114
Hong Kong 109
Hebei 93
Kraków 93
Munich 92
São Paulo 91
Tianjin 84
Grevenbroich 83
Jiaxing 75
Kunming 72
Changsha 68
Redondo Beach 61
Orem 56
Warsaw 55
Hangzhou 54
Hefei 52
Norwalk 52
Seoul 52
Jinan 46
Chicago 42
Pescara 42
Tokyo 42
Brooklyn 41
Brussels 41
Denver 41
Houston 40
Johannesburg 40
Montreal 40
Rome 40
Washington 40
Orange 39
Helsinki 37
Brno 36
Toronto 34
Chennai 33
Kocaeli 31
Phoenix 31
Atlanta 30
Guangzhou 30
Da Nang 29
Boston 28
Ningbo 28
Shanghai 28
Lanzhou 27
Rio de Janeiro 27
Seattle 27
St Louis 27
Haiphong 26
Mexico City 26
Zhengzhou 26
London 25
Poplar 25
Augusta 24
Frankfurt am Main 24
Hải Dương 24
Nuremberg 24
San Mateo 24
Belo Horizonte 23
Mumbai 23
Riyadh 23
Stockholm 23
Manchester 22
Amsterdam 21
Auburn Hills 21
San Francisco 21
Milan 20
Ankara 19
Camerino 19
Tashkent 19
Totale 21.097
Salva come PNG Salva come JPEG
Nome #
“DERIVATI ISOSSAZOLICI E LORO IMPIEGO COME INIBITORI DELLA CICLOOSSIGENASI” 237
Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer. 184
Antithrombotic Agents and Cancer 182
Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice. 162
Response to "Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance" 160
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 160
Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease. 156
Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells 154
Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts. 153
Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. 150
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. 150
The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. 148
Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting 147
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences 145
Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. 144
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease 143
ROLE OF DOSE POTENCY IN THE PREDICTION OF RISK OF MYOCARDIAL INFARCTION ASSOCIATED WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN THE GENERAL POPULATION. 142
Effects of estrogen on endothelial prostanoid production and cyclooxygenase-2 and heme oxygenase-1 expression. 142
Platelet-Derived Microparticles From Obese Individuals: Characterization of Number, Size, Proteomics, and Crosstalk With Cancer and Endothelial Cells. 142
Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. 139
Dysregulation of gene expression in human fetal endothelial cells from gestational diabetes in response to TGF-β1 138
Rare SNP rs12731181 in the miR-590-3p Target Site of the Prostaglandin F2α Receptor Gene Confers Risk for Essential Hypertension in the Han Chinese Population. 138
Thromboxane biosynthesis and pulmonary function in cystic fibrosis 137
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 137
LA CASCATA DELL'ACIDO ARACHIDONICO 136
Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century. 136
A comparison of low-dose aspirin and dazoxiben as selective inhibitors of thromboxane A2 production in man. 135
Aspirin after acute myocardial infarction: a systematic approach to compare the hemostatic effects of three different doses. 135
Effetto del propranololo e del suo metabolita attivo 4-OH propranololo sui prostanoidi COX-2 derivati e sull’emossigenasi-1 (OH-1) in cellule HUVEC. 134
New insights into COX-2 biology and inhibition. 132
Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation 132
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases 130
[ITALIAN CONSENSUS ON EULAR 2003 RECOMMENDATIONS FOR THE TREATMENT OF KNEE OSTEOARTHRITIS.] 130
Aspirin after acute myocardial infarction: a systematic approach to compare the hemostatic effects of three different doses. 130
Novel insights into the regulation of cyclooxygenase-2 expression by platelet-cancer cell cross-talk. 130
ALTERED RENAL AND PLATELET ARACHIDONIC ACID METABOLISM IN CIRRHOSIS. 129
Differential contribution of cycloooxygenase-isozymes to the generation of prostacyclin and prostaglandin E2 by endothelial cells in response to steady laminar shear stress 129
Therapeutic targeting of dysregulated cellular communication. 129
A double-blind randomized study of the anti-platelet effects of low-dose ASA and placebo in patients after myocardial infarction 128
PROSTAGLANDIN E2-MEDIATED ACTIVATION OF PHOSPHATIDYLINOSITOL 3-OH KINASE DIFFERENTIALLY AFFECTS IL-10 AND IL-1β PRODUCTION IN BLOOD CELLS. 128
ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS 128
Advances in NSAID development: Evolution of diclofenac products using pharmaceutical technology 128
Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems 128
Oxidative stress and platelet activation in essential hyperytension 127
Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. 127
Platelet activation in patients with colorectal cancer. 126
Clinical pharmacology of selective COX-2 inhibitors. 126
A class of pyrrole derivatives endowed with analgesic/anti-inflammatory activity. 126
Curbing tumorigenesis and malignant progression through the pharmacological control of the wound healing process. 126
Aspirin and Cancer 125
THE SELECTIVITY OF NOVEL COX-2 INHIBITORS IN HUMAN WHOLE BLOOD ASSAYS OF COX-ISOZYME ACTIVITY. 124
Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. 124
T-type channel blocking properties and antiabsence activity of two imidazo[1,2-b]pyridazine derivatives structurally related to indomethacin. 124
LOW-DOSE NAPROXEN INTERFERES WITH THE ANTIPLATELET EFFECT OF LOW-DOSE ASPIRIN IN HEALTHY SUBJECTS. 123
Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. 123
Induction of prostacyclin by steady laminar shear stress suppresses Tumor Necrosis Factor-alfa biosyntesis via Heme Oxygenase-1 in human endothelial cells. 123
Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. 123
Modulation of prostaglandin h synthase-2 (pghs-2) expression in human monocytes by glucocorticoids. 121
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 121
Aspirin, platelet inhibition and cancer prevention. 121
Biomarkers of Response to Low-Dose Aspirin in Familial Adenomatous Polyposis Patients 120
AMPLIFICATION LOOPS: THROMBOXANE GENERATION. 120
Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects 120
Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. 120
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. 120
Gut microbiota, host gene expression, and aging. 120
RECOVERY OF THROMBOXANE BIOSYNTHESIS BY ASPIRIN-TREATED PLATELETS IN VITRO: A NOVEL MECHANISM OF ASPIRIN RESISTANCE. 119
Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. 119
A SELECTIVE THROMBOXANE-SYNTHASE INHIBITOR, ON PLATELET AND RENAL PROSTAGLANDIN ENDOPEROXIDE METABOLISM 118
CLINICAL PHARMACOLOGY OF CYCLOOXYGENASE INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 118
De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. 118
INIBITORI SELETTIVI DI COX-2: LE NUOVE MOLECOLE 118
Risk management profile of etoricoxib: An example of personalized medicine 118
Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. 117
CYCLOOXYGENASE-2-DERIVED PROSTACYCLIN RESTRAIN PLATELET THROMBOXANE BIOSYNTHESIS IN TOLL-LIKE RECEPTOR 4 POLYMORPHISM 117
Clinical pharmacology of novel selective COX-2 inhibitors. 117
Platelets and extracellular vesicles in cancer: diagnostic and therapeutic implications 117
Determinants of platelet activation in human essential hypertension. 117
Usefulness of enzimatic intermediate markers-example of cox-2 inhibition 116
ACTIVATED POLYMORPHONUCLEAR LEUKOCYTES INDUCE A PRO-INFLAMMATORY STATE OF THE ENDOTHELIUM 116
OXIDATIVE STRESS AND PLATELET ACTIVATION IN HUMAN ESSENTIAL HYPERTENSION. 116
ANTIINFLAMMATORY COMPOUNDS L-745,337 AND NS-398 ARE SELECTIVE INHIBITORS OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 IN HUMAN BLOOD MONOCYTES 116
Mechanistic and pharmacological issues of aspirin as an anticancer agent 116
Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. 116
Editorial: Eicosanoids in Cancer 116
Increased thromboxane production by monocyte prostaglandin endoperoxide synthase-2 in patients with acute myocardial infarction (pubbl. su Suppl. Circulation) 115
Dose- Dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. 115
EFFECTS OF NIMESULIDE ON CONSTITUTIVE AND INDUCIBLE PROSTANOID BIOSYNTHESIS IN MAN. 115
The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. 115
Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. 115
Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. 115
Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies 115
INDUCTION OF PROSTACYCLIN BY STEADY LAMINAR SHEAR STRESS SUPPRESSES TUMOR NECROSIS FACTOR-ALPHA BIOSYNTHESIS VIA HEME OXYGENASE-1 IN HUMAN ENDOTHELIAL CELLS. 114
Mechanistic aspects of COX-2 expression in colorectal neoplasia. 114
In vitro morphine metabolism by rat microglia. 114
Incomplete suppression of platelet COX-1 activity associated with aspirin-resistant thromboxane biosynthesis in acute coronary syndromes 113
Platelets, cyclooxygenases, and colon cancer. 113
NSAIDs and cardiovascular disease. 113
Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo 113
Tumor-Educated Platelet Extracellular Vesicles: Proteomic Profiling and Crosstalk with Colorectal Cancer Cells 112
Totale 12.943
Salva come PNG Salva come JPEG
Categoria #
all - tutte 136.876
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 136.876
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021573 0 0 0 0 0 0 0 0 0 349 85 139
2021/20221.264 12 16 38 202 122 9 25 103 123 25 192 397
2022/20234.632 374 433 179 589 495 970 291 409 626 55 90 121
2023/20241.827 163 100 131 53 100 456 496 36 7 35 17 233
2024/20254.671 368 638 539 105 104 152 89 383 481 213 545 1.054
2025/202610.450 955 557 1.246 1.366 841 711 1.792 813 1.273 896 0 0
Totale 35.488